Sabby Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Sabby Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,109	Closed	-$1.95M	–	228
2021 Q3	$1.95M	Buy	1,109 +167	+18%	+$1.95K	0.26%	54
2021 Q2	$914K	Buy	942 +360	+62%	+$3.39K	0.13%	88
2021 Q1	$625K	Sell	582 -1,797	-76%	-$22.2K	0.12%	98
2020 Q4	$3.5M	Buy	+2,379	New	+$34.3K	0.67%	27
2020 Q3	–	Sell	-527	Closed	-$426K	–	160
2020 Q2	$426K	Buy	527 +76	+17%	+$470	0.09%	61
2020 Q1	$182K	Buy	+451	New	+$1.71K	0.08%	56

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Sabby Management's TRIL Position: Q4 2021 in Review

Sabby Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 70,000 shares — an estimated $1.23M sold.

Sabby Management first reported a position in TRIL in Q1 2016 and held it in 6 quarters. The position peaked at $2.14M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Sabby Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Sabby Management sold 70,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.23M.
Sabby Management first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 6 quarters.
Sabby Management's Trillium Therapeutics Inc. position peaked at $2.14M in Q1 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.